FDA’s Dermatological Drugs Advisory Committee
Executive Summary
Jan. 23-24 meeting canceled due to the inability of the committee to gather a quorum. The meeting was scheduled to discuss Ortho's 0.05% tretinoin cream (NDA 19-963) for photodamaged skin on Jan. 23 and to assess the continued marketing of benzoyl peroxide as an OTC acne product. The meeting will be rescheduled, probably for February or March, with the same agenda....